Blood Deheparinization Using Immobilized Microbial Heparinase

Authors
Linhardt, Robert J.
Langer, R.
Cooney, C.L.
Galliher, P.M.
Flanagan, M.M.
Hoffberg, S.M.
ORCID
https://orcid.org/0000-0003-2219-5833
Loading...
Thumbnail Image
Other Contributors
Issue Date
1981
Keywords
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Degree
Terms of Use
In Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
Full Citation
Blood Deheparinization Using Immobilized Microbial Heparinase, R.J. Linhardt, R. Langer, C.L. Cooney, P.M. Galliher, M.M. Flanagan, S.M. Hoffberg, Proceedings of the Second World Congress of Chemical Engineering, Montreal, Canada, Vol. I, pp. 183-185, 1981.
Abstract
Extracorporeal medical machines (e.g., artificial kidney, pump-oxygenator) perfused with blood have been an effective part of the therapeutic armamentarium for many years. These devices all rely on systemic heparinization to provide blood compatibility. Despite continuous efforts to improve anticoagulation techniques, many patients still develop coagulation abnormalities with the use of these devices (1,2,3). There is the prospect of even longer perfusion times with machines such as the membrane oxygenator. In such cases, the drawbacks of systemic heparinization are multiplied (4). A number of approaches have been attempted to solve this problem. These Include : 1) administration of compounds to neutralize heparin (5), 2) development of heparin substitutes (6), 3) bonding heparin (7-12) or other substances (13) to the extracorporeal device, and 4) development of new blood-compatible materials for construction of the extracorporeal device (14). In spite of these efforts, heparinization continues to be used extensively in all extracorporeal treatments and control of blood heparin levels remains a serious problem. We propose a new approach which would allow the full heparinization of the extracorporeal device yet which could enable elimination on-demand of heparin in the patient's bloodstream. This approach consists of a blood filter containing immobiized heparinase which could be placed at the effluent of any extracorporeal device (Figure 1). Such a filter could theoretically be used to eliminate heparin after it had served its purpose in the extracorporeal device and before it returned to the patient. In this report we discuss our efforts to develop such a filter. Our work has focused on several areas: 1) enzyme production, 2) enzyme purification, 3) characterization of heparinase, 4) immobilization of hepar1nase, and 5) 1n vitro testing of immobilized heparinase.
Description
Proceedings of the Second World Congress of Chemical Engineering, Montreal, Canada, Vol. I, pp. 183-185
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Department
The Linhardt Research Labs.
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
Publisher
Canadian Society for Chemical Engineering
Relationships
The Linhardt Research Labs Online Collection
Rensselaer Polytechnic Institute, Troy, NY
2nd [Second] World Congress of Chemical Engineering
https://harc.rpi.edu/
Access
A full text version is available in DSpace@RPI